港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

抗疫概念

878.789

-11.619-1.30%

漲家數：3

跌家數：14

平家數：- -

市盈率：- -

高：889.460

開：889.460

低：870.070

收：890.408

成交量：3.01億

成交額：22.54億

市值：5,928.82億

流通市值：4,916.77億

資料載入中...

勁方醫藥-B(02595)9月8日斥資154.18萬港元回購5.7萬股

智通财经网

禮邦醫藥-B(09637)：AP308治療IgA腎病的新藥臨床試驗申請獲美國食品藥品監督管理局批准

歌禮制藥-B(01672)在美國啓動口服胰澱素受體激動劑多肽ASC36 治療肥胖症的I期研究

中國生物製藥(01177)：TQH5528「口服STAT6降解劑」於ERS 2026公布臨床前研究數據

白雲山(00874.HK)：白雲山生物收到澳門成藥登記證書

石藥集團(01093.HK)：化藥創新藥SYH2083滴眼液在中國獲臨床試驗批准

白雲山：凍幹人用狂犬病疫苗獲澳門成藥登記證書

復星醫藥(600196.SH)子公司FXS5626片獲臨床試驗批准

復星醫藥：控股子公司藥品FXS5626獲臨床試驗批准

「底部整理+趨勢反彈」，開拓藥業-B(09939)何時站上估值反轉的關鍵節點？

港股異動 | 手機產業鏈跌幅居前多家主流手機廠商集體漲價全球出貨量持續萎縮

比亞迪電子（00285）盤中回調跌逾4% 機構指其H1純利按年大跌75%遜預期

平安好醫生(01833.HK)推「平安跨境康」以AI翻譯破解外籍人士來華就醫難題

阿斯达克财经

中國生物製藥（01177）盤中拉升6.86% 機構指創新管線已進入密集兑現期

港股生物醫藥股午後走強，劑泰科技-P漲近15%，百奧賽圖-B、金斯瑞生物科技漲近10%

老虎资讯综合

國藥控股（01099）宣佈與翰森製藥（03692）開啓全周期戰略協同合作

港股異動 | 中國生物製藥(01177)漲近3% TQC3721吸入粉霧劑已於ERS 2026公布I期臨床研究數據

港股異動 | 禮邦醫藥-B(09637.HK)升逾6% 納入港股通及恒生綜合指數落地美信羅銷售按年增約105% 商業化兑現

港股異動 | 禮邦醫藥-B(09637)升逾6% 納入港股通及恒生綜合指數落地美信羅銷售按年增約105% 商業化兑現

大瓜！券商醫藥研究員轉行看電子去了

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/hant/stock/BK1515/news?page=4"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK1515","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1515\",,,,,undefined,":{"symbol":"BK1515","market":"HK","secType":"PLATE","nameCN":"抗疫概念","latestPrice":878.7892,"timestamp":1789114133774,"preClose":890.4082,"halted":0,"volume":300625831,"delay":0,"changeRate":-0.013049,"floatShares":0,"shares":0,"eps":0,"marketStatus":"休市中","change":-11.619019,"latestTime":"09-11 16:00:00","open":889.45984,"high":889.45984,"low":870.06995,"amount":2253603899,"amplitude":0.021776,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1789349400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1789090200000,1789099200000],[1789102800000,1789113600000]],"pbRate":1.318473,"peRate":17.086203,"turnoverRate":0.003644,"increases":3,"decrements":14,"flats":0,"marketCap":592881820352,"floatMarketCap":491676687872},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1515\",,,,,undefined,":{"symbol":"BK1515","high":889.45984,"amplitude":0.021776,"preClose":890.4082,"low":870.06995,"pbRate":"1.318473","latestPrice":878.7892,"volume":300625831,"delay":0,"open":889.45984,"prevYearClose":1190.107,"prevWeekClose":936.431,"prevMonthClose":925.265,"prevQuarterClose":802.777,"fiveDayClose":936.431,"twentyDayClose":912.416,"sixtyDayClose":852.523,"secType":"PLATE","market":"HK","turnoverRate":0.003644,"peRate":17.086203,"marketCap":592881820352,"floatMarketCap":491676687872,"timestamp":1789114133774,"nameCN":"抗疫概念"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1515\",,,,undefined,":{"bkCode":"BK1515","up":3,"down":14,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1515\",pageSize:20,pageCount:4,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2665135320","title":"勁方醫藥-B(02595)9月8日斥資154.18萬港元回購5.7萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2665135320","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665135320?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 20:09","pubTimestamp":1788869377,"startTime":"0","endTime":"0","summary":"智通财经APP讯，劲方医药-B(02595)发布公告，于2026年9月8日，该公司斥资154.18万港元回购5.7万股。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493534.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1574","BK1515","09939","159938","BK1161","02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665320617","title":"禮邦醫藥-B(09637)：AP308治療IgA腎病的新藥臨床試驗申請獲美國食品藥品監督管理局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2665320617","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665320617?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 20:03","pubTimestamp":1788869000,"startTime":"0","endTime":"0","summary":"智通财经APP讯，礼邦医药-B 发布公告，公司近日就AP308的新药临床试验申请获美国食品药品监督管理局批准，将启动一项AP308用于治疗IgA肾病的首次人体临床试验。就公司所知，AP308为首个获准开展临床试验的IgA蛋白酶类IgAN候选药物。该平台具有优异的稳定性及成药性，并可在保留蛋白酶对IgA1高效切割活性的同时，显著延长药物体内半衰期、降低肾脏清除并减弱免疫原性，为长效、低频次给药奠定基础。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493525.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","09637","BK1161","159151","159938","MDTX","BK1515","BMED","IBBQ","BK1574","IBBJ","PSYK","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665503321","title":"歌禮制藥-B(01672)在美國啓動口服胰澱素受體激動劑多肽ASC36 治療肥胖症的I期研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2665503321","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665503321?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 18:04","pubTimestamp":1788861852,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B 发布公告，在近期获得美国食品药品监督管理局 批准新药临床试验后，其已启动ASC36口服片用于治疗肥胖症的美国I期研究。在非人灵长类动物中，ASC36口服片每日一次给药7天后，使平均体重相较基线下降高达13.2%。ASC36片亦显著减少了食物摄入。基于潜在更优的口服生物利用度和疗效，与近期获FDA批准的一款GLP-1R激动剂多肽相比，预计ASC36口服片的给药剂量更低。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493423.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01672","BK1574","01477","BK1515","BK1161","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665329142","title":"中國生物製藥(01177)：TQH5528「口服STAT6降解劑」於ERS 2026公布臨床前研究數據","url":"https://stock-news.laohu8.com/highlight/detail?id=2665329142","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665329142?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 17:52","pubTimestamp":1788861125,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药(01177)发布公告，集团附属公司正大天晴药业集团股份有限公司(“正大天晴”)自主研发的TQH5528“口服STAT6降解剂”已于欧洲呼吸学会2026年会(ERS 2026)上，以口头报告(Oral)形式公布临床前研究数据，并同步展示电子壁报(e-poster)。TQH5528是正大天晴基于全球自主知识产权的口服蛋白降解剂技术平台(OAPD®)开发的一款口服 STAT6降解剂。TQH5528靶向IL-4/IL-13/STAT6信号轴，依靠蛋白降解机制发挥药效，有潜力成为替代注射生物制剂、给药更便捷的新一代治疗药物。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493406.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"中国生物制药(01177)：TQH5528“口服STAT6降解剂”于ERS 2026公布临床前研究数据","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BZ08YT58.USD","BK1191","BK1521","BK1515","IE00BZ08YS42.EUR","BK1589","HK0000165453.HKD","IE00BZ08YR35.GBP","01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665329679","title":"白雲山(00874.HK)：白雲山生物收到澳門成藥登記證書","url":"https://stock-news.laohu8.com/highlight/detail?id=2665329679","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665329679?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 17:49","pubTimestamp":1788860950,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1606","BK1521","00874","BK1191","BK1515","BK1197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665296783","title":"石藥集團(01093.HK)：化藥創新藥SYH2083滴眼液在中國獲臨床試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2665296783","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665296783?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 17:48","pubTimestamp":1788860890,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0501845795.SGD","BK1515","LU1226287529.USD","LU1993786604.SGD","LU1813983027.USD","IE00B031HY20.USD","LU1951186391.HKD","IE0008369823.USD","IE00BZ08YT58.USD","BK1161","LU0067412154.USD","LU1226287792.SGD","HK0000165453.HKD","BK1521","KURE","LU1807302812.USD","IE00B543WZ88.USD","LU0326950275.SGD","06978","SG9999004220.SGD","LU0072913022.USD","LU1328277881.USD","IE0008368742.USD","LU0314109678.HKD","LU0315179316.USD","01093","LU1008478684.HKD","LU0140636845.USD","LU1152091754.HKD","BK1574","LU1226287875.USD","LU1226288170.HKD","IE00B5MMRT66.SGD","LU2039709279.SGD","IE00BZ08YR35.GBP","BK1191","LU0880133367.SGD","LU1960683339.HKD","LU1226288253.USD","IE00BZ08YS42.EUR","LU1152091168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665832608","title":"白雲山：凍幹人用狂犬病疫苗獲澳門成藥登記證書","url":"https://stock-news.laohu8.com/highlight/detail?id=2665832608","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665832608?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 17:20","pubTimestamp":1788859200,"startTime":"0","endTime":"0","summary":"9月8日，白云山（600332/00874）发布公告，公司合并报表范围内企业广州白云山生物制品股份有限公司收到澳门特别行政区政府药物监督管理局签发的《成药登记证书》。该证书涉及的药品为冻干人用狂犬病疫苗（Vero细胞），剂型为注射剂，类别为处方药。公司在冻干人用狂犬病疫苗（Vero细胞）的研发项目上已累计投入研发费用约2.05亿元（未经审计）。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609083868122111.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609083868122111.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1521","BK0096","BK1515","BK0012","159646","BK0175","BK0239","BK0183","00874","BK1191","BK1197","BK1606","600332","BK0070","BK0196","BK0028","BK0188","BK0097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665132698","title":"復星醫藥(600196.SH)子公司FXS5626片獲臨床試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2665132698","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665132698?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 17:13","pubTimestamp":1788858794,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药 发布公告，近日，公司控股子公司上海复星医药产业发展有限公司收到国家药品监督管理局关于同意FXS5626片用于治疗非节段型白癜风开展II/III期适应性无缝设计临床试验的批准。复星医药产业拟于条件具备后于中国境内开展该药品的相关临床研究。截至2026年8月，公司现阶段针对FXS5626的累计研发投入约为1.08亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493360.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1593","BK0028","BK0096","BK0196","BK0012","BK0187","BK0183","BK0060","BK0188","600196","BMED","BK0175","02196","IBBQ","BK1191","MDTX","BK1515","PSYK","BK0239","IBBJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665732638","title":"復星醫藥：控股子公司藥品FXS5626獲臨床試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2665732638","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665732638?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 16:59","pubTimestamp":1788857986,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0196","600196","BK1593","BK0012","BK0096","BK0188","BK0028","BK0187","BK0239","BK0175","02196","BK1191","BK1515","BK0183","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665932548","title":"「底部整理+趨勢反彈」，開拓藥業-B(09939)何時站上估值反轉的關鍵節點？","url":"https://stock-news.laohu8.com/highlight/detail?id=2665932548","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665932548?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 16:43","pubTimestamp":1788856994,"startTime":"0","endTime":"0","summary":"9月7日盘前，开拓药业-B发布公告，宣布其自主研发的抑制黑色素生成的新型高效酪氨酸酶抑制剂KT-939的人体长期安全性试验已于2026年9月4日顺利结束。初步数据显示，合计114位受试者连续52周使用KT-939后，未出现皮肤不良反应，且与该试验中期28周临床使用结果一致，充分展现了KT-939具有良好的安全性。在该利好消息刺激下，开拓药业股价当日开盘后迅速走高，半小时内涨幅拉升至9.89%，股价再次站上2港元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493326.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","09939","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665340720","title":"港股異動 | 手機產業鏈跌幅居前 多家主流手機廠商集體漲價 全球出貨量持續萎縮","url":"https://stock-news.laohu8.com/highlight/detail?id=2665340720","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665340720?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 15:12","pubTimestamp":1788851534,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1589","01478","BK1580","01415","BK1515","BK1167","LU0274383008.USD","BK1540","HK0000320264.USD","BK1179","LU0348767384.USD","BK1149","BK1504","BK1582","HK0000306701.USD","BK1607","HK0000306685.HKD","00285","LU0348766576.USD","HK0000320223.HKD","06613","BK1170","BK1096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665734087","title":"比亞迪電子（00285）盤中回調跌逾4% 機構指其H1純利按年大跌75%遜預期","url":"https://stock-news.laohu8.com/highlight/detail?id=2665734087","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665734087?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 14:34","pubTimestamp":1788849281,"startTime":"0","endTime":"0","summary":"金吾财讯 | 比亚迪电子（00285）盘中股价回调，截至发稿，最新报25.80港元，下跌4.02%，成交额2.14亿港元。消息面上，杰富瑞研报指，比亚迪电子上半年收入同比升2%，符合该行及市场预期，惟纯利同比大跌75%，远逊该行及市场预期，主要受约7亿元汇兑亏损拖累。毛利率同比收缩2个百分点至4.9%，亦低于该行及市场预期，主因高毛利组件贡献减少导致产品组合转差。该行将2026至2027年纯利预测下调最多29%，远低于市场预期；维持“持有”评级，目标价由29港元下调至25港元。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250110/NTQxOTRlZTU5ZGZkZjc4MmEzMTdjMTVhMTM1NjYxOTg3NzU=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/NTQxOTRlZTU5ZGZkZjc4MmEzMTdjMTVhMTM1NjYxOTg3NzU=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991018","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK1540","BK1589","LU0274383008.USD","BK1504","BK1580","BK1607","BK1582","LU0348767384.USD","BK1167","BK1149","LU0348766576.USD","00285"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665340584","title":"平安好醫生(01833.HK)推「平安跨境康」以AI翻譯破解外籍人士來華就醫難題","url":"https://stock-news.laohu8.com/highlight/detail?id=2665340584","media":"阿斯达克财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665340584?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 14:28","pubTimestamp":1788848880,"startTime":"0","endTime":"0","summary":"平安好医生(01833.HK) 旗下新品“平安跨境康”近日于深圳科创展正式亮相。针对外籍人士在华就医面临的语言障碍、流程不熟及服务断层等痛点，“平安跨境康”结合AI多语言实时翻译引擎与线上线下医疗服务闭环，提供一站式就医陪伴。目前，产品已率先于深圳开放体验。(su/j)(港股报价延迟最少十五分钟。沽空资料截至 2026-09-08 12:25。)AASTOCKS新闻","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20191015154325179_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20191015154325179_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1543384/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1543384/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1247","BK1142","BK1219","BK1615","BK1617","01833","BK1571","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665347968","title":"中國生物製藥（01177）盤中拉升6.86% 機構指創新管線已進入密集兑現期","url":"https://stock-news.laohu8.com/highlight/detail?id=2665347968","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665347968?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 14:14","pubTimestamp":1788848069,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中国生物制药（01177）午后持续拉升，截至发稿，最新报5.85港元，涨幅6.86%，成交额4.23亿港元。消息面上，国盛证券研究指，公司深度聚焦抗肿瘤、呼吸、肝病及代谢等重大疾病领域，创新管线已进入密集兑现期，有望推动公司加速发展。预计公司2026-2028年营业收入分别为351.41/390.33/437.12亿元，同比增速分别为10.39%/11.08%/11.99%。该机构表示，看好公司进入加速发展阶段，通过可比公司估值法，给予公司2027年27倍PE，对应目标价8.20元港币，首次覆盖，给予“买入”评级。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250110/NmI5OTlmYjAxY2FmOGFlNWZkYjg2NDM0MTE4MzUwMDcw.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/NmI5OTlmYjAxY2FmOGFlNWZkYjg2NDM0MTE4MzUwMDcw.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991016","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1521","IE00BZ08YR35.GBP","HK0000165453.HKD","BK1515","01177","IE00BZ08YS42.EUR","IE00BZ08YT58.USD","BK1191","BK1589"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113703587","title":"港股生物醫藥股午後走強，劑泰科技-P漲近15%，百奧賽圖-B、金斯瑞生物科技漲近10%","url":"https://stock-news.laohu8.com/highlight/detail?id=1113703587","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1113703587?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 13:33","pubTimestamp":1788845625,"startTime":"0","endTime":"0","summary":"9月8日，港股$生物(000504)$医药股午后走强，$剂泰科技-P(07666)$涨近15%，$百奥赛图-B(02315)$、$金斯瑞生物科技(01548)$涨近10%，$泰格医药(03347)$、$康希诺生物(06185)$、$云顶新耀(01952)$涨超5%。","market":"hk","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","HK0000306701.USD","VXUS","BK1574","01548","07666","BK1583","BK1576","06185","HK0000320264.USD","BK1515","BK4581","BK0216","09939","BK4585","02315","03347","KCAI","BK4588","BK1141","688796","BK1191","XBI","01952","399441","161726","HK0000320223.HKD","HK0000306685.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665334495","title":"國藥控股（01099）宣佈與翰森製藥（03692）開啓全周期戰略協同合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2665334495","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665334495?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 12:34","pubTimestamp":1788842076,"startTime":"0","endTime":"0","summary":"金吾财讯 | 国药控股（01099）9月8日宣布，近日，公司已与翰森制药（03692）达成战略合作。基于双方多年深度合作积淀，围绕深化工商协同、赋能产业高质量发展目标，双方签署战略合作协议，同步落地广阔市场、医疗准入、零售、DTP专项合作协议，推动工商合作由传统业务对接，全面升级为全链条、全周期战略协同。","market":"hk","thumbnail":"https://static.szfiu.com/news/20241108/MGM1MTEwODE5MDc1ODM4MQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MGM1MTEwODE5MDc1ODM4MQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991005","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1589","BK1583","BK1500","01099","BK1197","LU1115378108.SGD","03692","LU0640798160.USD","BK1515","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665634948","title":"港股異動 | 中國生物製藥(01177)漲近3% TQC3721吸入粉霧劑已於ERS 2026公布I期臨床研究數據","url":"https://stock-news.laohu8.com/highlight/detail?id=2665634948","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665634948?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 10:47","pubTimestamp":1788835637,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中国生物制药涨近3%，截至发稿，涨2.74%，报5.62港元，成交额1.11亿港元。消息面上，9月7日，中国生物制药发布公告，本集团附属公司正大天晴药业集团股份有限公司自主研发的TQC3721吸入粉雾剂已于欧洲呼吸学会2026年会上公布2项1期临床研究数据。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493179.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","KCAI","IE00BZ08YS42.EUR","HK0000165453.HKD","IE00BZ08YR35.GBP","BK1515","BK4585","BK1521","BK1589","VXUS","01177","IE00BZ08YT58.USD","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665349337","title":"港股異動 | 禮邦醫藥-B(09637.HK)升逾6% 納入港股通及恒生綜合指數落地 美信羅銷售按年增約105% 商業化兑現","url":"https://stock-news.laohu8.com/highlight/detail?id=2665349337","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665349337?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 10:16","pubTimestamp":1788833785,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09637","BK1161","HSCI","BK1515","09939","BK1191","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665334349","title":"港股異動 | 禮邦醫藥-B(09637)升逾6% 納入港股通及恒生綜合指數落地 美信羅銷售按年增約105% 商業化兑現","url":"https://stock-news.laohu8.com/highlight/detail?id=2665334349","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665334349?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 10:16","pubTimestamp":1788833785,"startTime":"0","endTime":"0","summary":"深交所9月7日公告亦确认09637调入港股通标的证券名单。礼邦医药于8月26日披露上市后首份中期业绩，2026年上半年收入人民币1.042亿元，同比增长761.2%，主要来自美信罗销售及AP306许可收入，期内亏损人民币1.626亿元，同比收窄22.5%。其中，商业化产品美信罗实现销售收入人民币2480万元，同比增长约105%，覆盖医院超300家，毛利率由2025年上半年的43.4%升至47.3%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493163.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","KCAI","09637","BK1515","09939","BK4585","159938","BK1191","VXUS","BK1574","FLHK","HSCI","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665312996","title":"大瓜！券商醫藥研究員轉行看電子去了","url":"https://stock-news.laohu8.com/highlight/detail?id=2665312996","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665312996?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 21:05","pubTimestamp":1788786300,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！（来源：花尔街之狼）券商医药研究员转行看电子去了本科硕士都学的医学，怎么转行看电子了？","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-09-07/doc-iniqzhfu5386610.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["KCE","159938","BK1515","BK1161","BK1574","09939"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":11,"pageCount":4,"totalSize":219,"code":"91000000","status":"200"}]}}